1. Home
  2. ANAB vs IIIN Comparison

ANAB vs IIIN Comparison

Compare ANAB & IIIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • IIIN
  • Stock Information
  • Founded
  • ANAB 2005
  • IIIN 1953
  • Country
  • ANAB United States
  • IIIN United States
  • Employees
  • ANAB N/A
  • IIIN N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • IIIN Steel/Iron Ore
  • Sector
  • ANAB Health Care
  • IIIN Industrials
  • Exchange
  • ANAB Nasdaq
  • IIIN Nasdaq
  • Market Cap
  • ANAB 600.4M
  • IIIN 587.8M
  • IPO Year
  • ANAB 2017
  • IIIN N/A
  • Fundamental
  • Price
  • ANAB $22.27
  • IIIN $30.46
  • Analyst Decision
  • ANAB Buy
  • IIIN
  • Analyst Count
  • ANAB 11
  • IIIN 0
  • Target Price
  • ANAB $54.64
  • IIIN N/A
  • AVG Volume (30 Days)
  • ANAB 623.5K
  • IIIN 105.9K
  • Earning Date
  • ANAB 11-05-2024
  • IIIN 01-16-2025
  • Dividend Yield
  • ANAB N/A
  • IIIN 0.39%
  • EPS Growth
  • ANAB N/A
  • IIIN N/A
  • EPS
  • ANAB N/A
  • IIIN 0.99
  • Revenue
  • ANAB $57,172,000.00
  • IIIN $529,198,000.00
  • Revenue This Year
  • ANAB $207.49
  • IIIN $9.60
  • Revenue Next Year
  • ANAB N/A
  • IIIN $16.98
  • P/E Ratio
  • ANAB N/A
  • IIIN $30.78
  • Revenue Growth
  • ANAB 282.17
  • IIIN N/A
  • 52 Week Low
  • ANAB $13.36
  • IIIN $26.74
  • 52 Week High
  • ANAB $41.31
  • IIIN $39.38
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 42.41
  • IIIN 58.84
  • Support Level
  • ANAB $18.03
  • IIIN $29.19
  • Resistance Level
  • ANAB $22.94
  • IIIN $30.63
  • Average True Range (ATR)
  • ANAB 1.37
  • IIIN 0.63
  • MACD
  • ANAB 0.45
  • IIIN 0.18
  • Stochastic Oscillator
  • ANAB 86.18
  • IIIN 94.05

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About IIIN Insteel Industries Inc.

Insteel Industries Inc manufactures steel wire reinforcing products for concrete construction applications. It manufactures and markets PC strand and welded wire reinforcement, including ESM, concrete pipe reinforcement, and standard welded wire reinforcement. The company's products are sold to manufacturers of concrete products that are used in nonresidential construction. Its concrete reinforcing products consist of two product lines: PC strand and WWR. Insteel generates its geographical revenue from the United States.

Share on Social Networks: